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Pontes RB, Crajoinas RO, Nishi EE, Oliveira-Sales EB, Girardi AC,
Campos RR, Bergamaschi CT. Renal nerve stimulation leads to the
activation of the Na/H exchanger isoform 3 via angiotensin II type I
receptor. Am J Physiol Renal Physiol 308: F848–F856, 2015. First published
February 11, 2015; doi:10.1152/ajprenal.00515.2014.—Renal nerve stim-
ulation at a low frequency (below 2 Hz) causes water and sodium
reabsorption via 1-adrenoreceptor tubular activation, a process inde-
pendent of changes in systemic blood pressure, renal blood flow, or
glomerular filtration rate. However, the underlying mechanism of the
reabsorption of sodium is not fully understood. Since the sympathetic
nervous system and intrarenal ANG II appear to act synergistically to
mediate the process of sodium reabsorption, we hypothesized that
low-frequency acute electrical stimulation of the renal nerve (ESRN)
activates NHE3-mediated sodium reabsorption via ANG II AT1 re-
ceptor activation in Wistar rats. We found that ESRN significantly
increased urinary angiotensinogen excretion and renal cortical ANG II
content, but not the circulating angiotensinogen levels, and also
decreased urinary flow and pH and sodium excretion via mechanisms
independent of alterations in creatinine clearance. Urinary cAMP
excretion was reduced, as was renal cortical PKA activity. ESRN
significantly increased NHE3 activity and abundance in the apical
microvillar domain of the proximal tubule, decreased the ratio of
phosphorylated NHE3 at serine 552/total NHE3, but did not alter total
cortical NHE3 abundance. All responses mediated by ESRN were
completely abolished by a losartan-mediated AT1 receptor blockade.
Taken together, our results demonstrate that higher NHE3-mediated
proximal tubular sodium reabsorption induced by ESRN occurs via
intrarenal renin angiotensin system activation and triggering of the
AT1 receptor/inhibitory G-protein signaling pathway, which leads to
inhibition of cAMP formation and reduction of PKA activity.
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THE IMPORTANCE OF THE renal nerve in regulating extracellular
volume has been reported in different physiological and patho-
physiological conditions (17, 20, 26, 52, 60). It has been
postulated that the renal nerve serves as a link between the
kidneys and the central nervous system (19). The role of the
renal nerve has important clinical implications, since renal
denervation has been used to treat patients with resistant
hypertension, which seems to effectively reduce blood pressure
for periods of up to 3 years (7, 37).
To understand the influence of the sympathetic nervous
system (SNS) on the kidneys, different techniques have been
widely used (5, 6, 51). In an experimental model of increased
renal sympathetic nerve activity (rSNA) induced by environ-
mental stress, both urinary retention and sodium retention were
completely abolished by renal denervation (35), demonstrating
the role of sympathetic innervation on handling of salt and
water by the kidneys. rSNA influences the renal function by
increasing renin secretion, decreasing renal blood flow and
glomerular filtration rate (GFR), and enhancing tubular sodium
reabsorption. Electrical stimulation of the renal nerve (ESRN)
induces these responses in a frequency-dependent manner (19).
However, neither renal sodium nor water handling is influ-
enced exclusively by the SNS, since both circulating and local
ANG II have direct and indirect actions on renal tubular transport
(23, 44, 53). In fact, ANG II directly increases fluid and bicar-
bonate reabsorption of proximal tubules in vitro (4) and increases
sodium transport in isolated proximal tubules (54).
Circulating ANG II also acts in brain regions devoid of the
blood-brain barrier, leading to SNS activation to the kidney
(39, 41). The positive feedback between ANG II and SNS has
been linked to both physiological and pathophysiological con-
ditions (18). There are clear evidences upon an interdependent
between the SNS and ANG II on the kidney (38, 51, 52). The
proximal tubule is responsible for the reabsorption of the
majority of filtered sodium, bicarbonate, chloride, and water.
The principal apical membrane pathway for sodium reabsorp-
tion in the proximal tubule involves an NHE3-mediated
Na/H exchanger. Apical NHE3 transport also figures prom-
inently in chloride and water reabsorption in the proximal
tubule, as isotonic reabsorption occurs across a highly perme-
able epithelium (2). NHE3-mediated sodium reabsorption is
regulated by various physiological conditions and molecular
mechanisms, including phosphorylation, regulatory proteins,
and redistribution along brush border microvilli (9).
Healy and colleagues (24) demonstrated that direct electrical
renal nerve stimulation has antinatriuretic and antidiuretic
effects associated with increased NHE3 activity within the
membranes of brush border. However, the signaling and mo-
lecular mechanisms underlying such increases, as much as the
role of ANG II involved in this response, are not well under-
stood. Because ANG II is an important mediator of sodium
reabsorption in the proximal tubule, we tested the hypothesis
that intrarenal ANG II may mediate the majority of the anti-
natriuretic and antidiuretic actions of the rSNA.
METHODS
Materials. Ketamine and xylazine were obtained from Syntec
(Cotia, SP, Brazil). Sodium thiopental was obtained from Cristália
(Itapira, SP, Brazil). A monoclonal antibody to NHE3 was a gift from
Dr. Peter Aronson (Yale University, New Haven, CT). A phospho-
specific mAb that recognizes NHE3 only when it is phosphorylated at
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serine 552 (PS552) was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA) and a mAb to actin (clone JLA20) was purchased
from Merck (Darmstadt, Germany). An anti-phosphorylated serine/
threonine (pSer/Thr) PKA substrate antibody was purchased from
Cell Signaling Technology (Beverly, MA). Horseradish peroxidase-
conjugated goat anti-mouse and goat anti-rabbit secondary antibodies
were purchased from Life Technologies (Carlsbad, CA). All other
reagents were purchased from Sigma Chemical (St. Louis, MO)
unless otherwise stated.
Animals and study design. All experimental procedures were per-
formed in accordance with the guidelines established by the Institutional
Animal Care Committee of the Ethics in Research Committee of the
Universidade Federal de São Paulo (protocol no. 0361/11). Male Wistar
rats (n  45, 250–300 g) were obtained from the animal care facility of
Universidade Federal de São Paulo. All animals were housed in group
cages, given free access to rat chow and water, and maintained in a
temperature-controlled environment (23°C) on a 12:12-h light-dark cycle.
The animals were anesthetized with ketamine and xylazine (100 and 20
mg/kg ip, respectively), and their right kidneys were retroperitoneally
exposed and removed to avoid influence of the contralateral kidney on
any observed responses. The animals were allowed to recover until the
day of the experiment. After 7–8 days following uninephrectomy, the
animals were divided into the following three groups: Sham, in which
the animals’ rSNA was recorded for 1 h; Stimulated (S), in which the
animals were subjected to ESRN for 1 h; and Stimulated and treated with
losartan (SL), in which the animals received a single bolus injection of
losartan (10 mg/kg iv) 1 h prior to undergoing ESRN. This dose causes
tubular natriuresis without causing blood pressure alterations in this
condition (25, 61). At this time, animals were anesthetized with sodium
thiopental (60 mg/kg ip) and were subsequently tracheotomized. The
femoral vein was catheterized with a PE-10 polyethylene tube, which was
connected to a PE-50 for the administration of additional anesthetic (10
mg·kg1·h1 iv) and isotonic saline at 10 ml·kg1·h1. The femoral
artery was cannulated for direct arterial pressure measurements. The
animals’ rectal temperature was maintained at 37°C with a servo-con-
trolled electric blanket (Letica). The femoral artery catheter was con-
nected to a pressure transducer, and arterial pressures were recorded
online (PowerLab, ADInstruments). The ureter was catheterized with
polyethylene tubing (PE-10) to collect urine for posterior analyses.
rSNA in sham rats. The renal nerve was localized by use of a
dissecting microscope, freed from connective tissue, and positioned
on a bipolar silver recording electrode. Both the renal nerve and
electrode were covered with paraffin oil. The signal of the renal nerve
was displayed on an oscilloscope and nerve activity was amplified
(gain 20,000, Neurolog, Digitimer), filtered with a band-pass filter
(100–1,000 Hz), and collected for display and analysis by using a
PowerLab data-acquisition system (ADInstruments).
ESRN. In both the S and SL groups the renal nerve was localized and
dissected as described above, and then stimulated at 15 mV, 1.5 Hz, and
0.5 ms over a period of 1 h by using a stimulating electrode connected to
an electrical stimulator system (Grass S88). We tested amplitudes to
determine the amount sufficient to generate evocated potential from the
renal nerve fibers. The median value obtained was 4 mV. Once the evocated
potential occurred there was no additional difference in the amplitude
of evoked potential, even following increases in voltage stimulation.
At the end of the experiments, blood was collected from the femoral
artery, and the left kidney was removed and placed in PBS containing
1 tablet/50 ml of Complete Protease Inhibitor Cocktail Tablets
(Roche, Mannheim, Germany) and phosphatase inhibitors (50 mM
NaF and 15 mM sodium pyrophosphate), pH 7.4.
Analysis of basal rSNA. Nerve activity was analyzed offline with
appropriate software (Spike Histogram, ADInstruments). For this pur-
pose, the raw nerve signal was passed through a spike discriminator
(PowerLab, ADInstruments) to remove background noise. The number
of spikes was counted with a spike discriminator that excluded back-
ground noise, which was determined for each experiment (63).
Blood and urine analyses. At the end of experiment, we collected
blood and urine samples to posterior analyses. Urinary flow was
determined by measuring urinary volumes normalized to body weight
obtained over a period of 1 h. Plasma (PNa) and urinary sodium (UNa)
concentrations were measured with an electrolyte analyzer (AVL
Medical Instruments). Creatinine clearance was used to estimate GFR.
Plasma (PCr) and urinary creatinine (UCr) concentrations were mea-
sured via a kinetic method (Labtest, Minas Gerais, Brazil) using a
Thermo Plate Analyzer Plus (Thermo Plate, São Paulo, Brazil).
Fractional sodium excretion (FENa) was calculated as follows: FENa 
100·(UNa/PNa)/(UCr/PCr). We measured urinary angiotensinogen
(AGT) using an ELISA (Rat Total Angiotensinogen Assay Kit,
Clontech Laboratories) according to the manufacturer’s instructions
and plasma AGT via immunoblotting. Urinary cAMP was measured
by using an ELISA kit (DetectXTM direct cAMP enzyme immuno-
assay kit, Arbor Assays) according to the manufacturer’s instructions
(21).
Cortical renal homogenate and membrane protein isolation. Kid-
ney cortices were isolated at 4°C and homogenized in ice-cold PBS
buffer (10 mM phosphate, 140 mM NaCl, pH 7.4) containing protease
inhibitors [0.7 mg/ml pepstatin, 0.5 mg/ml leupeptin, 40 mg/ml
PMSF, and 1 tablet/50 ml of Complete Protease Inhibitor Cocktail
Tablets (Roche)] and phosphatase inhibitors (50 mM NaF and 15 mM
sodium pyrophosphate). Aliquots of the crude homogenate were saved
for measuring the contents of ANG II, and the remainder was
centrifuged at 4,000 g for 10 min at 4°C. The supernatant was
removed and subjected to an additional 90 min of centrifugation at
28,000 g at 4°C. The supernatant was discarded, and the pellets were
resuspended in fresh PBS containing protease and phosphatase inhib-
itors. Protein concentrations were measured by Lowry’s method (43).
Determination of ANG II content in renal cortical homogenate.
ANG II levels in renal cortical homogenates were measured by
competitive ELISA (Phoenix Pharmaceuticals, Burlingame, CA) ac-
cording to the manufacturer’s instructions (50).
Renal cortical PKA activity. PKA activity was indirectly measured
via immunoblotting. Equal amounts (25 g) of plasma membrane
protein isolated from rat renal cortices were resolved by SDS-PAGE
and analyzed via immunoblotting using a specific antibody that
recognizes phosphorylated PKA substrates (16). Visualized bands
were digitized with an Image Scanner (GE HealthCare) and quantified
with the Scion Image Software package (Scion, Frederick, MD).
Microvillar membrane vesicle preparation. Rat kidney cortices
were isolated at 4°C and homogenized in a K-HEPES buffer (200 mM
mannitol, 80 mM HEPES, 41 mM KOH, pH 7.5) containing protease
and phosphatase inhibitors. Microvillus membrane vesicles were pre-
pared by a method based on Mg2 precipitation and differential
centrifugation as described previously (1).
SDS-PAGE and immunoblotting. Renal cortical membrane and
microvillar membrane vesicle (MMV) proteins isolated from each of
the rat groups and 0.5 l of plasma were solubilized in sample buffer
(2% SDS, 20% glycerol, 100 mM -mercaptoethanol, 50 mM Tris,
pH 6.8, 0.05% bromophenol blue) and separated by SDS-PAGE using
7.5% polyacrylamide gel. Proteins were then transferred from the
polyacrylamide gel to a polyvinylidene difluoride microporous membrane
(Immobilon-P, Millipore, Bedford, MA) and incubated by blocking
solution (5% nonfat dry milk and 0.1% Tween 20 in PBS buffer, pH
7.0) for 1 h at room temperature to block nonspecific binding before
being incubated overnight with 1:500 anti-NHE3, 1:1,000 anti-PS552-
NHE3 (monoclonal antibody to serine 552 phosphorylated NHE3),
1:1,000 anti-pSer/Thr, or 1:5,000 anti-actin at 4°C in blocking solu-
tion. The membranes were then washed five times in blocking solution
and incubated for 1 h with horseradish peroxidase-conjugated immu-
noglobulin secondary antibody (1:2,000) before being washed and
additional five times with blocking solution and subsequently rinsed
with either PBS or TBS buffer. Bound antibody was detected via
enhanced chemiluminescence (ECL, GE Healthcare, Piscataway, NJ)
according to manufacturer’s instructions. Visualized bands were dig-
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itized by using an Image Scanner LAS 4,000 mini (GE Health Care)
and quantified with ImageJ software.
Determination of NHE3 activity in MMV. NHE3-mediated
Na/H exchange activity in MMV was determined by using the
acridine orange fluorescent technique as described previously (8).
MMVs (100 g) were resuspended in a 500-l sodium-free buffer
containing 140 mM N-methyl-D-glucamine (NMDG) gluconate and 5
mM MES (pH 5.5). Subsequently 20 l of the acid-load MMVs were
added to 100 l of 120 mM NMDG-gluconate, 20 mM K-HEPES, pH
7.5, and 6 M acridine orange (Molecular Probes, Eugene, OR).
Experiments were performed on a 96-well black plate. The fluores-
cence signal was monitored and recorded at 0.5-s intervals for 1 min
(VICTOR 2 Plate Reader, Perkin Elmer, Waltham, MA). After 2 min,
Na gluconate was added to a final concentration of 200 mM per well.
Na/H exchange activity was defined as the rate of change of
acridine orange fluorescence in the presence of sodium per second
divided by the initial quenching in the acridine orange fluorescence
signal obtained by the addition of the MMV. Each sample was
analyzed in triplicate. Some experiments were performed in the
presence of 10 M (S3226) (55).
Statistics analysis. All results are reported as means  SE. Com-
parisons among groups were performed by one-way ANOVA fol-
lowed by Newman-Keuls post hoc test. A P value 	 0.05 was
considered to be statistically significant.
RESULTS
Experimental characterization. We performed a right ne-
phrectomy to avoid any influence on our results by the con-
tralateral kidney. As shown in Table 1, no differences in body
Table 1. Differences among experimental groups
Sham S SL
Body weight, g 300 8 (n  6) 307  4 (n  6) 302  3 (n  6)
Kidney weight, g 1.5  0.1 (n  6) 1.6  0.1 (n  6) 1.5  0.01 (n  6)
Ratio, kidney weight/body weight
100 0.50 0.02 (n  6) 0.50  0.02 (n  6) 0.50  0.01 (n  6)
MAP baseline, mmHg 103 2 (n  10) 109  3 (n  9) 108  3 (n  10)
MAP end, mmHg 89  2 (n  10) 90  3 (n  9) 88  3 (n  10)
Baseline rSNA tonus, spikes/s 93  4 (n  10) 93  3 (n  9) 88  3 (n  10)
End rSNA tonus, spikes/s 89  5 (n  10)
Values are means  SE; n, number of rats per group. S, Stimulated group, in which the animals were subjected to electrical stimulation of the renal nerve
(ESRN) for 1 h; SL, Stimulated and treated with Losartan group, in which the animals received a single bolus injection of Losartan (10 mg/kg iv) 1 h prior to
undergoing ESRN; MAP, mean arterial blood pressure; rSNA, renal sympathetic nerve activity.
Fig. 1. Effects of acute electrical stimulation of
the renal nerve (ESRN) on urinary and circulat-
ing angiotensinogen (AGT) levels. A: circulating
angiotensinogen levels were determined via im-
munoblotting. Top: an equal volume of plasma
(0.5 l) from each animal was subjected to
SDS-PAGE, transferred to a polyvinylidene di-
fluoride (PVDF) membrane, and incubated with
a polyclonal antibody against angiotensinogen.
Membranes were stained with Ponceau S prior
to antibody incubation, and the protein albumin
was used as an internal control. There was no
difference in circulating angiotensinogen among
the groups. Bottom: the relative abundance of
angiotensinogen/albumin was quantitated via
densitometry. B: urinary angiotensinogen levels
were determined via ELISA. The number of rats
in each group is depicted within the bar graphs.
Compared with Sham group, activity of the
intrarenal renin-angiotensin system (RAS) was
increased by ESRN [98% higher in acute ESRN
(S) and 100% in acute ESRN pretreated with
losartan (SL) groups] (Fig. 1B). C: renal cortical
ANG II levels were determined via competitive
ELISA. ANG II were significantly higher (304%
in S and 337% in SL) compared with Sham.
Values are means  SE. *P 	 0.05 vs. Sham.
Values are means  SE. *P 	 0.05 vs. Sham.
F850 RENAL NERVE STIMULATION AND NHE3-MEDIATED SODIUM REABSORPTION
AJP-Renal Physiol • doi:10.1152/ajprenal.00515.2014 • www.ajprenal.org
weight, kidney weight, and ratio of kidney weight to body
weight were observed among the three experimental groups
following uninephrectomy. Each of the groups demonstrated
similar basal blood pressures and rSNA. Neither S nor SL
groups demonstrated alterations in blood pressure during the
experiment, similar to the Sham group (Table 1).
ESRN activates intrarenal but not systemic renin-angioten-
sin system. AGT is a valuable marker of the renin-angiotensin
system (RAS) in humans and rodents (27, 31). Plasma AGT
represents systemic RAS, and urinary AGT represents intrare-
nal RAS. We evaluated the effects of ESRN on both circulating
and urinary AGT to determine whether increased rSNA would
lead to activation of either the intrarenal or systemic RAS. As
illustrated in Fig. 1A, ESRN caused no changes in systemic
RAS. However, compared with the Sham group, the activity of
the intrarenal RAS was increased in both the S and SL groups
by 98 and 100%, respectively (Fig. 1B).
To further confirm the effect of ESRN on renal RAS, the
content of ANG II was measured in renal cortical homogenates
by competitive ELISA. Similar to urinary AGT, the levels of
ANG II were significantly higher in both S (1.55  0.16 vs.
0.51  0.11 ng/g, P 	 0.001) and SL (1.72  0.17 vs. 0.51 
0.11 ng/g, P 	 0.001) compared with Sham (Fig. 1C).
Effects of ESRN on renal function. Figure 2 demonstrates the
acute effects of ESRN and ESRN plus losartan on renal
function. ESRN significantly reduced urinary flow (Fig. 2A)
and urinary sodium excretion (Fig. 2B). These antidiuretic and
antinatriuretic effects were not accompanied by changes in
creatinine clearance (Fig. 2C). However, ESRN reduced frac-
tional sodium excretion (Fig. 2D) and urinary pH (Fig. 2E),
strongly suggesting that the antidiuretic and antinatriuretic
effects of ESRN were due, in part, to increased Na/H
exchange. All renal function responses elicited by ESRN were
abolished by treatment with the AT1 blocker losartan.
Role of the AT1/Gi signaling pathway in mediating the
effects of ESRN on renal tubular Na/H exchange. NHE3 is
the Na/H exchanger isoform that plays a crucial role in
acid-base and volume homeostasis by handling the majority of
Fig. 2. Effects of acute ESRN on renal func-
tion in rats treated or not with losartan. A:
urinary flow. B: urinary sodium excretion. C:
creatinine clearance was used to estimate the
glomerular filtration rate (GFR). D: frac-
tional sodium excretion (FENa) was calcu-
lated as CNa/CCr where CNa is Na clear-
ance and CCr is creatinine clearance. Renal
functional data were corrected by body
weight (BW) and expressed per kilogram of
BW. E: urinary pH. The number of rats in
each group is depicted within the bar graphs.
Values are means  SE. *P 	 0.05 vs.
Sham.
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sodium, chloride, and bicarbonate reabsorption that occurs in
the proximal tubule of the nephron (46). Immunoblotting
experiments were undertaken to test the hypothesis that ESRN
directly affects renal cortical NHE3 expression and phosphor-
ylation levels. As shown in Fig. 3A, total cortical NHE3
expression was unchanged in response to ESRN; however, the
ratio of phosphorylated NHE3 to total NHE3 at serine 552 was
reduced by as much as 46%. Pretreatment with losartan abol-
ished the effects of ESRN on NHE3 phosphorylation levels.
Phosphorylation at serine 552 represents a mechanism of
PKA-mediated inhibition of endogenously expressed NHE3
(34). Thus the results shown in Figs. 2 and 3 suggest that
ESRN increases tubular Na and water reabsorption by in-
creasing NHE3-mediated Na/H exchange via AT1. This
hypothesis was addressed by measuring NHE3 activity and
abundance in MMV isolated from Sham, S, and SL experi-
mental groups (Fig. 4). Figure 4A shows that ESRN increases
NHE3-mediated Na/H exchange in MMV by 40  6%
compared with Sham. Pretreatment with losartan completely
prevented the ESRN-mediated upregulation of NHE3 activity.
Kocinsky and colleagues (34) have found that, when NHE3
is phosphorylated at serine 552, the exchanger is mainly
confined to coated pit region of the brush-border membrane.
We therefore postulated that reduced PKA-mediated phosphor-
ylation of NHE3 induced by ESRN may lead to redistribution
of NHE3 to the microvilli domain of the brush border. Ac-
cordingly, as shown in Fig. 4B, NHE3 abundance was 40%
higher in MMVs isolated from S rats than in Sham. Addition-
ally, no difference was observed on the abundance of NHE3 in
MMV isolated from SL compared with Sham.
The effects of ANG II in the renal tubules are due primarily
to the activation of AT1 receptors, which are present in both
apical and basolateral membranes of the proximal tubules. The
binding of ANG II to AT1 receptors at these locations results in
the inhibition of adenylyl cyclase and increased Na reabsorp-
tion (56). Therefore, the reduction of cAMP levels, which
results in lower PKA activity, may be one of the mechanisms
by which NHE3 is activated by ANG II in response to ESRN.
To test this hypothesis, both the urinary concentration of
cAMP (Fig. 5) and renal cortical PKA activity (Fig. 6) were
measured in our experimental groups. As demonstrated in Fig.
5, ESRN decreased urinary cAMP by 66% and an AT1 block-
ade completely abolished the effects of ESRN on urinary
excretion of cAMP (88  5 vs. 100  4%, P 	 0.05).
Additionally, rats subjected to ESRN exhibited reduced levels
of phosphorylated PKA substrates in the renal cortex (Fig. 6)
compared with Sham rats (60  7 vs. 100  10%). ESRN-
induced PKA inhibition was completely blunted by injection of
losartan (Sham: vs. S vs. SL: 96  3 vs. 100  10%).
DISCUSSION
The primary finding of the present study was that ESRN
increased the NHE3-mediated sodium transport via AT1 recep-
tor activation. This effect was mediated by the intrarenal RAS
and was not influenced by either systemic or renal hemody-
namic alterations. Increased NHE3 transport activity induced
antinatriuresis and antidiuresis. These responses were com-
pletely abolished by the injection of losartan. Therefore, the
effects of ESRN on sodium and water reabsorption are highly
dependent on the AT1 receptor.
ESRN decreased both urinary volume and urinary sodium
excretion by as much as 61%, and fractional excretion of
sodium by as much as 56%, with no change in creatinine
clearance. Our functional results were similar to those of prior
studies (5, 19). The possibility that changes in GFR in response
to renal stimulation altered sodium reabsorption was ruled out,
because we did not observe any changes in creatinine clear-
ance. ESRN below 2 Hz does not cause reduction in renal
blood flow or GFR in rats (5, 14, 19). Furthermore, the levels
Fig. 3. Effects of acute ESRN on renal cortical NHE3 expression and
phosphorylation levels in rats treated or not with losartan. Equivalent samples
(15 g for NHE3 and 5 g for PS552-NHE3) of renal cortical membranes
isolated from Sham rats, rats subjected to acute ESRN (S), and rats subjected
to acute ESRN pretreated with losartan (SL) were subjected to SDS-PAGE,
transferred to a PVDF membrane, and analyzed via immunoblotting. A: the
membranes were incubated with monoclonal antibody against phosphorylated
NHE3 at serine 552 (1:1,000), total NHE3 (1:500) and anti-actin (1:5,000).
Graphical representation of the relative expression levels of total (B) and
phosphorylated (C) NHE3 in renal cortical membranes. The number of rats in
each group is depicted within the bar graphs. Values are means  SE. *P 	
0.05 vs. Sham.
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of MAP and rSNA remained stable throughout the experi-
ments. Therefore, the effects of ESRN on renal function were
not related to hemodynamic changes.
The renal proximal tubule reabsorbs most of the sodium,
bicarbonate, and chloride and water filtered by the glomerulus,
which strongly influences both extracellular fluid volume and
blood pressure (45). The primary transporter involved in prox-
imal tubule reabsorption is NHE3 (2). NHE3 reabsorbs sodium
and secretes hydrogen (2, 45). As we observed decreases in
both urinary sodium and in urinary pH, increased NHE3
transport secondary to ESRN is very likely. Indeed, ESRN
increased microvillar NHE3 transport activity by 40%.
The proximal tubule is richly innervated by the sympathetic
nerve fibers (3), which strongly suggests that SNS plays an
important role at this portion of the nephron. Acute renal
denervation reduces proximal tubular reabsorption (6, 13),
whereas renal nerve activation increases (5, 36, 51) proximal
tubular reabsorption. Therefore, these responses appear to be
the result of adrenergic neurotransmitters acting on adrenergic
receptors.
The role of the adrenergic receptors in renal proximal tubule
volume reabsorption is well established (11, 12). The mi-
croperfusion of norepinephrine in peritubular capillaries in-
creased the proximal reabsorption of bicarbonate (11) and
water (12), a process that was completely abolished by the
-adrenoceptor antagonist phenoxybenzamine. Interestingly,
the infusions of norepinephrine and phenoxybenzamine into
the proximal tubule did not change fluid and bicarbonate
reabsorption rates, clarifying the role of adrenoceptors at the
basolateral membrane as regulators proximal tubular reabsorp-
tion (11, 12).
A previous study demonstrated that acute denervation or
ANG converting enzyme inhibitor decrease the rates of prox-
imal tubule volume reabsorption at the same magnitude. How-
ever, intratubular infusions of ANG II restored proximal reab-
sorption to basal levels, even in the absence of renal innerva-
tion, demonstrating the influence of SNS on tonic intrarenal
RAS in the setting of acute conditions (52). Accordingly, the
antinatriuretic and antidiuretic effects observed in the present
Fig. 5. Effects of acute ESRN on renal urinary excretion of cAMP in rats
treated or not with losartan. cAMP urine concentration from Sham rats, rats
subjected to acute ESRN (S), and rats subjected to acute ESRN pretreated with
losartan (SL) was evaluated by ELISA and then adjusted for urinary flow. The
number of rats in each group is depicted within the bar graphs. Values are
means  SE. *P 	 0.05 vs. Sham.
Fig. 4. Effects of acute ESRN on NHE3 activity and abundance in apical
microvillar membrane vesicles (MMV) isolated from rats treated or not with
losartan. A: NHE3 activity was measured in MMV from Sham rats, rats
subjected to acute ESRN (S), and rats subjected to acute ESRN pretreated with
losartan (SL) as the reappearance of acridine orange from acid-loaded MMVs.
Experiments were performed in the presence or absence of the specific NHE3
inhibitor S3226 (10 mM). Each sample was analyzed in triplicate, and the
mean value of 4–5 rats from each group was calculated. B, top: NHE3 protein
abundance in MMV was evaluated by immunoblotting. Equal amounts of
protein (10 g) from each animal were subjected to SDS-PAGE, transferred to
a PVDF membrane, and incubated with the antibody anti-NHE3 (clone 3H3)
(1:500) or actin (1:50,000). Bottom: graphical representation of the relative
expression levels of NHE3 in MMV. The number of rats in each group is
depicted within the bar graphs. Values are means  SE. *P 	 0.05 vs. Sham.
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study were dependent on the AT1 receptors. Moreover, present
study demonstrated that AT1 receptors are involved in NHE3-
mediated sodium reabsorption in response to ESRN. In line
with our findings it has been demonstrated that AT1 blockade
prevented nerve-mediated antinatriuresis and antidiuresis fol-
lowing air-jet stress (58). The same group later postulated the
term “functional denervation” after they observed that an AT1
blockade blunted volume retention in experimental cirrhotic
rats exposed to an acute volume load (57). Our functional data
confirmed the interaction between the SNS and ANG.
In the present study, we demonstrated that the ESRN-
mediated increases in NHE3-mediated sodium reabsorption are
due to increased intrarenal ANG II (Fig. 7). The binding of
ANG II to its corresponding receptors results in the inhibition
of adenylyl cyclase and in increased Na reabsorption (56).
NHE3 is inhibited via phosphorylation by PKA (15, 34, 64),
and reductions in cAMP levels may be one of the mechanisms
by which NHE3 is activated by ANG II (42, 59). Accordingly,
we observed that ESRN activates the intrarenal RAS, decreases
urinary cAMP excretion, and reduces renal cortical PKA ac-
tivity. ESRN also decreases the ratio of NHE3 PS552/total
NHE3 but does not affect total NHE3. Therefore, our results
strongly support the proposed mechanism shown in Fig. 7 in
which ANG II couples with an inhibitory G protein and
subsequently reduces cAMP synthesis, resulting in reduced
PKA-mediated inhibition of NHE3.
The phosphorylation of NHE3 at serine 552 has been im-
plicated in NHE3 subcellular redistribution (22). Kocinsky and
colleagues (33) demonstrated that NHE3 phosphorylated at
serine 552 predominantly localizes to the coated pit domain of
the brush border. Recently, Brasen and colleagues (10) devel-
oped a mathematical model suggesting that NHE3 localized
exclusively at the base of the brush border results in local pH
microdomains, which reduces NHE3 activity by 30%. Our
results demonstrate that ESRN increases NHE3 abundance in
MMV without altering total cortical NHE3 expression,
strongly suggesting that ESRN modulates NHE3 subcellular
distribution. Accordingly, studies by the McDonough (62), Yip
(40), and Johns (24) groups demonstrated that NHE3 redistrib-
utes from the base to the body of the microvilli in response to
rSNA activation. Therefore, it appears that lower levels of
NHE3 phosphorylation at serine 552 triggered by ESRN/ANG
II/AT1 activation may be necessary to increase the distribution
of the exchanger in the body of the microvilli and subsequently
bolster its transport capabilities.
ESRN increased urinary AGT but not plasma AGT. Urinary
AGT is a valuable marker of intratubular RAS in human
pathophysiological conditions (28) and in rats under experi-
Fig. 6. Effects of acute ESRN on renal cortical activity of PKA in rats treated
or not with losartan. Phosphorylation levels of PKA substrates in renal cortical
plasma membranes of Sham rats, rats subjected to acute ESRN (S), and rats
subjected to acute ESRN pretreated with losartan (SL) were evaluated via
immunoblotting. A: equal amounts of protein (15 g) from each animal were
subjected to SDS-PAGE, transferred to a PVDF membrane, and incubated with
the antibody anti- phosphorylated serine/threonine (pSer/Thr). Actin was used
as an internal control. B: the sum total of all phospho-PKA proteins per lane
was estimated via densitometry and normalized by actin. The combined data
from 5 rats per group are represented as columns in a bar graph. Values are
means  SE. *P 	 0.05 vs. Sham group.
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Fig. 7. Model for the signaling mechanism by which ESRN lowers renal Na
excretion: ESRN activates intrarenal RAS; ANG II acts on an AT1 receptor and
activates a G protein, which reduces cAMP synthesis. Reduced cAMP gener-
ation leads to decreased PKA activity and prevents PKA-mediated inhibition
of NHE3. The triggering of the ESRN/ANG II/AT1 signaling cascade results
in antidiuresis and antinatriuresis, as well as higher bicarbonate reabsorption
via activation of proximal tubule NHE3-mediated Na/H exchange.
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mental conditions (47). In both chronic hypertensive humans
(49) and rats (32), AT1 antagonist treatment decreased urinary
AGT probably via inhibition of positive feedback mechanism
by ANG II (29, 30, 32, 47). We found that a single injection of
losartan followed by ESRN increased urinary AGT. We be-
lieve that the positive feedback by ANG II did not occur in our
condition considering that we performed our experiments
acutely in normotensive rats.
ESRN increased urinary AGT as well as renal cortical ANG
II content in both the S and SL groups at the same magnitude.
These results indicate that ESRN increases intrarenal RAS,
even in the presence of an AT1 receptor blockade. In fact, SNS
increases the activity of the intrarenal RAS independently of
alterations in plasma (48). Furthermore, it also indicates that
functional and molecular changes induced by the ESRN were
due to the AT1 receptor rather than intrarenal RAS activation.
These finds firmly establish that increases in NHE3 transport
by ANG II occur primarily via AT1 receptors.
Altogether, our results demonstrate that acute physiological
increases in rSNA activate intrarenal AT1 receptors, which
subsequently increases NHE3-mediated transport and results in
antinatriuresis and antidiuresis.
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